Previous studies have shown that inhibition of CYP2E1 effectively blocked hepatic ROS production with LPO, reduced liver injury, and inhibited NAFLD progression (Fig. 4I) [4–6, 22]. Here, CYP2E1 is linked to metabolic dysfunction-associated steatotic liver disease.